



FORM 13  
 (See rule 46)

CERTIFICATE OF TEST OR ANALYSIS BY GOVERNMENT ANALYST UNDER  
 SECTION 25(1) OF THE DRUGS AND COSMETICS ACT, 1940

- Name of Inspector from whom received : SARAH LALDINTLUANGI, ASSISTANT DIRECTOR (FOOD DRUGS)  
Sr. CMO Office  
Serchhip-796181
- Serial No. and date of Inspector's memorandum : 004/IPA/2024 , 25-NOV-2024
- Number of Sample : nil
- Date of receipt : 26-DEC-2024
- Names of drugs purporting to be contained in the sample : Glimepiride Tablets IP (GLIMESTAR-2)

Lab. Sample No.	Report No.	Batch No.	Date of Mfg.	Date of Exp.	Mfg. By
LSD/GUW/2024-25/1563	GUW/LS/2024-25/1587	B75W004	Apr-2023	Mar-2025	Mankind Pharma Ltd., Doring Block, Bermiok Elaka, South Sikkim-737 126.

6. Condition of seals on : Seals were intact & identical to the specimen impression of the seal received from Drugs Inspector  
 [the packet or on portion of sample or container]

7. Result of test or analysis with protocols or test or analysis applied : Please see below

Date of Testing : From 10-Jan-2025 To 17-Jan-2025

COMPOSITION : Each uncoated tablet contains: Glimepiride IP 2 mg.

**Protocol Applied : I.P. 2022**

Sr No.	Test Name	Result	Limits
1	Description	Light pink colored, round, flat , having a dosage line on one surface, uncoated tablets, in blister pack.	NA
2	Identification	Gives positive test for Glimepiride.	NA
3	Average weight	0.2028 g	NA
4	Dissolution	Complies.	NLT 75 % of claim

**Assay**

Sr.No	Ingredient Name	Found	Claim	% of claim	Limits	Procedure / Method
1	Glimepiride	2.09 mg/Tablet	2 mg/Tablet	104.5	90 % to 110 %	I.P. 2022

In the opinion of the undersigned the sample referred to above is of **standard quality** as defined in the Drugs and Cosmetics Act, 1940, and Rules there under for the reasons given below:-

**The sample conform to claim as per I.P. 2022 in respect of test performed.**

Date: 22-JAN-2025

*Rinku Kalita*  
GOVERNMENT ANALYST

Rinku Kalita  
Government Analyst  
R.D.T.L., Guwahati-22

----- END OF REPORT -----

